USP22 and neoplasm: USP22 also regulates normal cell-cycle progression; hence, nanocarrier- or tumor-targeted delivery systems are required to improve the therapeutic index and guard against resistance driven by compensatory activation of other deubiquitinases or epigenetic regulators.